Sildenafil Citrate Tablet, Film Coated
Product Images NDC 43063-941

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Sildenafil Citrate (NDC 43063-941). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

43063941 Label (43063941)

43063941 Label (43063941)
This is a package of Sildenafil tablets, each containing 50 mg of Sildenafil Citrate USP. The tablets are blue, round, and come in a container with 15 tablets. The lot number is D20C41 and they expire in September 2020. The product is from JINCORPORATED in Oklahoma City, OK. It is important to call a doctor if any side effects occur and to report them to the FDA. The instructions indicate the number of tablets to take each day but the frequency is not provided.*
FDA Label Image

Chemical Structure

Chemical Structure
FDA Label Image

Figure 1

Figure 1
The given text seems to be a clinical trial report of an experiment conducted on the effect of Sildenafil 100mg on blood pressure. The numbers indicate the systolic blood pressure in mmHg. The term 'Pre-Dose' suggests that the readings were taken before administering the dose, and 'Time post dose' may indicate the time elapsed after dosing. 'PLACEBO' and 'SLDENAFIL 100mg' are mentioned, which could indicate the experimental and control groups in the study. However, without further context, it is difficult to draw any definitive conclusions.*
FDA Label Image

Figure 2

Figure 2
The text describes a graph that shows the change in systolic blood pressure (SBP) in mmHg over time (in hours) postdose for two groups: one receiving Doxazosin and placebo, and the other receiving Doxazosin and Sildenafil 25 mg. It is not possible to determine the precise results from the given text.*
FDA Label Image

Figure 3

Figure 3
This appears to be a graph showing the change in SBP (systolic blood pressure) in mmHG, over time post-dose in hours, for two different treatments: "Doxazosin + Placebo" and "Doxazosin + Sildenafil 50 mg." The values on the x-axis range from 1 to 8, and the y-axis ranges from 0 to 40 mmHg.*
FDA Label Image

Figure 4

Figure 4
This text describes a graph showing the time after taking a medication containing Doxazosin and either Sildenafil or Placebo. The units of measurement on the graph are in mmHg, but the context of the text is not sufficient to provide further details or explanation.*
FDA Label Image

Figure 5

Figure 5
FDA Label Image

Figure 6 1

Figure 6 1
The text appears to represent numerical data related to patients and their scores, but without additional context or information, it is not possible to generate a useful description.*
FDA Label Image

Figure 6 2

Figure 6 2
FDA Label Image

Figure 7

Figure 7
This is a chart or table showing the percentage of patients who reported improvement while taking different doses of sildenafil citrate compared with a placebo. The doses of sildenafil citrate were 25mg, 50mg, and 100mg. The table shows that 100% of patients on the placebo reported improvement, while 82%, 74%, and 63% of patients on the different doses of sildenafil citrate reported improvement.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.